Pseudorotaxane capped mesoporous silica nanoparticles for 3,4-methylenedioxymethamphetamine (MDMA) detection in water by Lozano-Torres, Beatriz et al.
 Document downloaded from: 
 

























Lozano-Torres, B.; Pascual, L.; Bernardos Bau, A.; Marcos Martínez, MD.; Jeppesen, JO.;
Salinas Soler, Y.; Martínez-Máñez, R.... (2017). Pseudorotaxane capped mesoporous silica
nanoparticles for 3,4-methylenedioxymethamphetamine (MDMA) detection in water.
Chemical Communications. 53(25):3559-3562. https://doi.org/10.1039/c7cc00186j
https://doi.org/10.1039/c7cc00186j
The Royal Society of Chemistry
Chemical Communications c7cc00186j
Pseudorotaxane Q1capped mesoporous silica
nanoparticles for 3,4-methylenedioxy-
methamphetamine Q2(MDMA) detection in water
Beatriz Lozano-Torres, Lluis Pascual, Andrea Bernardos,
Marı´a D. Marcos, Jan O. Jeppesen, Yolanda Salinas,
Ramo´n Martı´nez-Ma´n˜ez* and Fe´lix Sanceno´n*
MDMA, a principal ecstasy component, is detected by
using pseudorotaxane-capped mesoporous silica
nanoparticles.
Please check this proof carefully. Our staff will not read it in detail after you have returned it.
Translation errors between word-processor files and typesetting systems can occur so the whole proof needs to be read.
Please pay particular attention to: tabulated material; equations; numerical data; figures and graphics; and references. If you
have not already indicated the corresponding author(s) please mark their name(s) with an asterisk. Please e-mail a list of
corrections or the PDF with electronic notes attached – do not change the text within the PDF file or send a revised
manuscript. Corrections at this stage should be minor and not involve extensive changes. All corrections must be sent at the
same time.
Please bear in mind that minor layout improvements, e.g. in line breaking, table widths and graphic placement, are
routinely applied to the final version.
Please note that, in the typefaces we use, an italic vee looks like this: n, and a Greek nu looks like this: n.
We will publish articles on the web as soon as possible after receiving your corrections; no late corrections will be made.
Please return your final corrections, where possible within 48 hours of receipt, by e-mail to: chemcomm@rsc.org
Queries for the attention of the authors
Journal: ChemComm
Paper: c7cc00186j
Title: Pseudorotaxane capped mesoporous silica nanoparticles for 3,4-methylenedioxy-
methamphetamine (MDMA) detection in water
Editor’s queries are marked on your proof like this Q1, Q2, etc. and for your convenience line numbers are
indicated like this 5, 10, 15, ...
Please ensure that all queries are answered when returning your proof corrections so that publication of your
article is not delayed.
Query
reference Query Remarks
Q1 For your information: You can cite this article before you
receive notification of the page numbers by using the
following format: (authors), Chem. Commun., (year), DOI:
10.1039/c7cc00186j.
Q2 Please carefully check the spelling of all author names.
This is important for the correct indexing and future
citation of your article. No late corrections can be made.
Q3 Address c appears to be incomplete. Do you wish to
provide any further details? If so, please provide the
details.
Pseudorotaxane Q1 Q2capped mesoporous silica
nanoparticles for 3,4-methylenedioxy-
methamphetamine (MDMA) detection in water†
Beatriz Lozano-Torres,abc Lluis Pascual,abc Andrea Bernardos,abc
Marı´a D. Marcos,abc Jan O. Jeppesen,d Yolanda Salinas,e Ramo´n Martı´nez-
Ma´n˜ez*abc and Fe´lix Sanceno´n*abc
Mesoporous silica nanoparticles loaded with fluorescein and
capped by a pseudorotaxane, formed between a naphthalene
derivative and cyclobis(paraquat-p-phenylene) (CBPQT4+), were
used for the selective and sensitive fluorogenic detection of 3,4-
methylenedioxymethamphetamine (MDMA).
Consumption and abuse of drugs is a problem of general concern
in our society and a number of agencies and authorities are on alert
to detect and stop illegal drug trade.1 Inside the vast realm of drugs,
3,4-methylenedioxymethamphetamine (MDMA), commonly known
as ecstasy, is one of the most widely consumed.2 MDMA is a
psychostimulant used primarily as a recreational drug.3 The effects
of MDMA include increased empathy, euphoria and heightened
sensations.4 When taken by mouth, the effects begin after 30–45
minutes and last for 3–6 hours.5 It is also sometimes snorted, orally
ingested or smoked.6 The adverse effects of MDMA include addic-
tion, memory problems, paranoia, difficulty in sleeping, teeth
grinding, blurred vision, sweating and a rapid heartbeat. Consump-
tion may also lead to depression and fatigue.7 Moreover, deaths
have been reported due to increased body temperature and
dehydration.8 Normally, MDMA is usually detected and quantified
by using capillary electrophoresis, near infrared spectroscopy, gas
chromatography and liquid chromatography.9 However, these
methods require the use of expensive technical equipment under
the supervision of trained personnel. Moreover, there has also been
an interest in the design and development of methods for rapid
‘‘in situ’’ detection of MDMA and in this context detection techni-
ques based on the use of portable ion mobility spectrometers,
Fourier transform infrared and Raman spectrometers and colori-
metric tests (Mandelin, Mecke and Simon) have been developed.10
In this scenario, the design of simple to use chromo-fluorogenic
probes for selective and sensitive MDMA detection is highly
appealing.
From another point of view, gated materials have found
remarkable applications as controlled release devices, especially in
the design of advanced drug delivery systems.11 Moreover, gated
materials have also been applied in sensing and recognition proto-
cols as an alternative to classical chromo-fluorogenic molecular
probes.12 These sensing ‘‘gated materials’’ are prepared using an
inorganic porous support, which is loaded with a reporter and then
capped with a gating scaffold that allows a selective cargo release
upon interaction with a target analyte.13 These new sensing systems
are clearly different from classic ‘‘binding site-signalling subunit’’
molecular-based systems because they make signalling independent
of the binding siteanalyte interaction. Besides, the use of ‘‘gated
materials’’ allows sensing systems with amplification features to be
obtained because the presence of few analyte molecules can induce
the release of large quantities of reporter molecules.14
Pseudorotaxanes are complex supramolecular systems con-
taining one or more macrocyclic rings encircling a rodlike
component. Rotaxane- and pseudorotaxane-based systems have
been widely used in the design of artificial machines that have
found use in applications such as molecular switches and
molecular shuttles.15 One of the most used macrocycles in
the preparation of rotaxanes and pseudorotaxanes is cyclobis
(paraquat-p-phenylene) (CBPQT4+), also known as ‘‘blue box’’.16
This macrocycle, composed of two electron deficient paraquat
subunits, forms strong inclusion complexes with electron
donating guests such as benzene and naphthalene derivatives
functionalised with donor atoms and neurotransmitters.17
In addition, rotaxanes and pseudorotaxanes have also been
applied in the design of gated materials. Since the first example
reported by Stoddart, Zink and co-workers,18 several examples


























a Instituto Interuniversitario de Investigacio´n de Reconocimiento Molecular y
Desarrollo Tecnolo´gico (IDM). Universitat Polite´cnica de Valencia, Universitat de
Valencia, Spain
b Departamento de Quı´mica, Universidad Polite´cnica de Valencia, Camino de Vera
s/n, 46022, Valencia, Spain. E-mail: rmaez@qim.upv.es, fsanceno@upvnet.upv.es
c CIBER de Bioingenierı´a, Biomateriales y Nanomedicina (CIBER-BBN),Q3
d Department of Physics, Chemistry, and Pharmacy, University of Southern
Denmark, Campusvej 55, 5230, Odense M, Denmark
e Institute of Polymer Chemistry (ICP), Johannes Kepler University Linz, Altenberger
Str. 69, 4040 Linz, Austria
† Electronic supplementary information (ESI) available: Synthesis and character-
ization of compound 3 and solids S1 and S2. See DOI: 10.1039/c7cc00186j
Received 9th January 2017,
Accepted 28th February 2017
DOI: 10.1039/c7cc00186j
rsc.li/chemcomm
This journal is c The Royal Society of Chemistry 2017 Chem. Commun., 2017, 00, 14 | 1
ChemComm
COMMUNICATION
macrocycle, by both chemical and photochemical inputs, allows
payload delivery.19 However, to the best of our knowledge,
materials gated with pseudorotaxanes have never been used
for the design of gated probes for sensing applications.
Bearing these facts inmind and our interest in the development
of gated hybrid materials for their application in new sensing
protocols,20 herein, we report the synthesis and characterisation
of mesoporous silica nanoparticles (S2 in Scheme 1) loaded with
fluorescein and functionalised on the external surface with a
pseudorotaxane (formed between a grafted naphthalene derivative
and the CBPQT4+ macrocycle) followed by their use for the selective
fluorogenic detection of MDMA. The underlying idea is that the
capped material would remain closed, yet in the presence of
MDMA, CBPQT4+ would detach from the surface of the nano-
particles with subsequent fluorescein release (see Scheme 1).
Dethreading of the capping pseudorotaxane is expected to occur
due to the formation of strong MDMAC CBPQT4+ donor acceptor
supramolecular complexes.
MCM-41 nanoparticles were prepared following well-known
procedures using tetraethylorthosilicate (TEOS) as a hydrolytic
inorganic precursor and hexadecyltrimethylammonium bro-
mide (CTABr) as a micellar template.21 The as-made solid was
then calcined at 550 1C to obtain the starting nanoparticles
with empty pores. Pores were loaded with fluorescein (solid S0)
and the external surface was functionalised with the naphtha-
lene derivative 3 (see Scheme 2) yielding S1 nanoparticles. The
final sensory material S2 was obtained after stirring an aqueous
suspension of S1 and the [CBPQT][PF6]4 macrocycle (see the
ESI† for experimental details). The naphthalene derivative 3
was synthesised from 1-naphthol (1) (see also Scheme 2). 1 was
alkylated with 2-bromoethanol, using a Williamson ether synth-
esis, yielding 2. Finally, 3 was obtained from the reaction
between 2 and (3-isocyanatopropyl)triethoxysilane.
The prepared solids were characterised using standard
techniques, e.g. powder X-ray diffraction (PXRD), transmission
electron microscopy (TEM), N2 adsorption–desorption isotherms
and elemental and thermogravimetric analyses. The structure of
the as-made and calcined MCM-41 nanoparticles was confirmed
by PXRD (see curves a and b in Fig. 1). The structure of the
nanoparticles was also confirmed by TEM studies (see Fig. 2e), in
which the spherical morphology and the mesoporous structure
of the material were clearly observed. N2 adsorption–desorption
isotherms of the calcined nanoparticles showed a typical type IV
curve for mesoporous materials (see ESI†). With the application
of BET and BJH models, a specific surface area of 1260.3 m2 g1,
a pore size of 2.31 nm and a pore volume of 0.54 cm3 g1 were
calculated. The PXRD pattern of S1 and S2 shows the character-
istic (100) diffraction peak (curves c and d in Fig. 1). The N2
adsorption–desorption isotherm of S1 showed a marked reduced
pore volume (0.36 cm3 g1) and surface area (849.0 m2 g1),
when compared with the starting nanoparticles. Thermogravi-
metric and elemental analysis studies indicated an organic
matter content of 15.2% in S1 (0.87 and 0.80 mmol g1 of solid
for fluorescein and 3 respectively) and 24.4% in S2 (0.83, 0.73
and 0.23 mmol g1 of solid for fluorescein, 3 and CBPQT4+
respectively). Besides, the addition of CBPQT4+ clearly inhibited

























Scheme 1 Mesoporous silica nanoparticles loaded with fluorescein and
capped with a pseudorotaxane formed between a grafted naphthol
derivative and CBPQT4+ (S2). Dethreading of the pseudorotaxane in the
presence of MDMA induced fluorescein release.
Scheme 2 (a) Synthetic procedure used for the preparation of naphtha-
lene derivative 3. (b) Chemical structure of MDMA and the drugs used as
potential interferents.
Fig. 1 Top: powder X-ray diffraction (PXRD) patterns of solids (a) MCM-41
as synthesized, (b) calcined mesoporous silica nanoparticles, (c) solid S1
and (d) S2 nanoparticles. Bottom: TEM images of (e) calcined MCM-41, (f)
solid S1 and (g) S2 nanoparticles, showing the typical porosity of the
mesoporous silica matrix.
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formation of naphthalene C CBPQT4+ inclusion complexes.
Moreover, TEM images of S2 showed the typical porosity of a
mesoporous silica matrix (see Fig. 2g).
After characterisation of the prepared materials, the con-
trolled release of fluorescein from S2 in the presence and
absence of MDMA was studied. For this purpose, S2 was added
to water at pH 7.00 and the suspension was separated in two
aliquots. MDMA was added to one aliquot whereas water was
added to the other. Both suspensions were stirred at 25 1C and
aliquots of 150 mL were taken at programmed times, centri-
fuged to remove the solid and the emission of the released
fluorescein was measured at 520 nm (lexc = 495 nm). The
release profiles obtained are shown in Fig. 2.
As can be seen, in the absence of MDMA, a very low cargo release
was observed indicating that S2 nanoparticles were tightly closed by
the pseudorotaxanes formed between 3 and CBPQT4+. However,
when MDMA was present in the solution, a remarkable enhance-
ment in the fluorescence at 520 nm was found. This emission
enhancement was ascribed to pore opening and fluorescein release
due to a preferential coordination of MDMA with CBPQT4+ (calcu-
lated constant from 1H-NMR titrations logK = 2.65  0.25) that
induced the dethreading of the pseudorotaxane grafted onto the
external surface of solidS2. The crucial role played by CBPQT4+ in the
gating mechanism was assessed by measuring the delivery profiles
of the uncapped solid S1 in the absence and presence of MDMA. A
marked fluorescein release was observed in both cases (see ESI†)
pointing out the importance of grafted pseudorotaxane in the
controlled release features of S2.
In a further step, to assess the selective response of S2
nanoparticles toward MDMA, the fluorogenic response of the
CBPQT4+-capped solid was tested in the presence of cocaine,
heroin, methadone and morphine (see Scheme 2). Fig. 3a
shows the emission (at 520 nm) due to fluorescein release after
10 min upon addition of selected drugs (10 mmol) to aqueous
suspensions of S2. Inspection of Fig. 3a reveals that the S2
nanoparticles are highly selective toward MDMA and other
drugs were unable to induce a marked fluorescein release. This
suggested that S2 or similar systems could be used for the
detection of MDMA.
The observed selectivity of S2 nanoparticles toward MDMA
could be explained bearing in mind that this drug forms strong
inclusion complexes with CBPQT4+. The remarkable stability of
these complexes resulted from the well-defined cavity of
CBPQT4+, which is formed by two electron-acceptor paraquat
groups separated by about 3.7 Å, which is ideally sized for the
inclusion of an electron-rich aromatic subunit such as that in
MDMA by donor–acceptor interactions. In order to demon-
strate the formation of MDMA C CBPQT4+ complexes
1H NMR studies in D2O were carried out. As can be seen in
Fig. 4, the aromatic part of the CBPQT4+ spectrum showed three
signals centered at 7.64, 8.33 and 9.13 ppm. The singlet
centered at 7.64 ppm can be ascribed to the resonances
associated with the protons of the p-phenylene bridges (Ha in
the structure of CBPQT4+ in Fig. 4), whereas the doublets
resonating at 8.33 and 9.13 ppm, respectively, can be assigned
to the protons on paraquat units (Hb and Hc protons, respec-
tively). As can be seen in the set of spectra shown in Fig. 4,
addition of increasing quantities of MDMA induced moderate
chemical shifts of the three CBPQT4+ aromatic protons and the
most remarkable are the downfield shifts observed for Ha (0.06
ppm) and Hc (0.03 ppm) protons. These downfield shifts are
consistent with the formation of donor–acceptor complexes by
the inclusion of the electron donor MDMA into the electron
accepting cavity of CBPQT4+.
Then, in order to test the sensitivity of S2, the fluorogenic
response of water suspensions of the nanoparticles upon addi-
tion of increasing amounts of MDMA was studied. The fluor-
escein emission at 520 nm was gradually enhanced with
increasing MDMA concentrations (see ESI†). From the titration
profile, a limit of detection of 4.9 mM (0.95 mg mL1) for MDMA
was determined.
Finally, the ability of S2 to detect MDMA in a more realistic
sample was tested. For this purpose we prepared an ecstasy
tablet by mixing MDMA and commonly used additives (i.e.
sucrose, chalk and paracetamol, see ESI†). Then we measured
the emission intensity of fluorescein released from S2 in the
presence of the individual components mixed together or
alone. The results obtained are depicted in Fig. 3b which shows

























Fig. 2 Release profiles of fluorescein from aqueous suspensions of solid
S2 at pH 7.0 in the absence and presence of MDMA (10 mmol). Error bars
are expressed as 3s.
Fig. 3 (a) Emission intensity of fluorescein at 520 nm (excitation at
495 nm) released from S2 nanoparticles (water pH 7.0) in the presence
of selected drugs (10 mmol) after 10 min of addition. (b) Emission intensity
of fluorescein at 520 nm (excitation at 495 nm) released from S2 nano-
particles (water pH 7.0) in the presence of components of an ecstasy
tablet.
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components) is able to induce pseudorotaxane dethreading,
pore opening and fluorescein release.
In summary, we have shown here a new protocol for the
selective and sensitive fluorogenic detection of MDMA by using
capped nanoparticles. Our sensing material consisted of meso-
porous silica nanoparticles loaded with fluorescein and capped by a
pseudorotaxane formed by a grafted naphthalene derivative and
the CBPQT4+ macrocycle. The sensing mechanism arises from a
displacement reaction by the formation of an inclusion complex
between MDMA and CBPQT4+ that detaches the macrocycle from
the surface of the nanoparticles. The fluorogenic response obtained
is highly selective, and other drugs (i.e. morphine, methadone,
heroin and cocaine) were unable to induce any significant fluores-
cence response. Besides, the sensitivity of capped nanoparticles is
remarkable with an MDMA limit of detection of 4.9 mM in water.
Taking into account the sensitivity and selectivity of solid S2 and its
easy synthesis and handling, this material could be used as a probe
for an accurate ‘‘in situ’’ and ‘‘at site’’ MDMA identification from
other illicit drugs.
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Fig. 4 1H NMR spectra (400 MHz, 298 K) recorded in D2O of CBPQT
4+ in
the presence of increasing quantities of MDMA.
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